肾细胞癌伴静脉瘤栓的免疫原性异质性研究
该研究对6例透明细胞肾细胞癌伴静脉瘤栓患者行根治性肾切除及瘤栓取出术,采用RNA测序及CIBERSORT、xCell等计算工具评估免疫细胞浸润与PD-L1表达。发现原发灶与瘤栓中M1巨噬细胞比例均较高,PD-L1高表达原发灶中M1巨噬细胞和静息NK细胞更多,瘤栓PD-L1表达可能与原发灶不一致。
要点
- 肾肿瘤瘤栓中M1巨噬细胞水平较高,可能作为未来药物开发的额外靶点。
- 透明细胞肾细胞癌活检的PD-L1表达可能不能代表其对应瘤栓的PD-L1表达。
- 平均血小板体积与PD-L1表达呈负相关,但需未来研究证实其作为血液生物标志物的潜力。
核心结论
- 肾肿瘤瘤栓具有较高水平的M1巨噬细胞,可能作为未来药物开发的额外靶点。
- 透明细胞肾细胞癌活检的PD-L1表达可能不能代表其对应瘤栓的PD-L1表达。
- 平均血小板体积作为肾细胞癌PD-L1表达潜在血液生物标志物需未来研究证实。
研究设计与样本
- 经IRB批准并获手术同意后,6例患者接受根治性肾切除联合静脉瘤栓取出术。
- 采用RNA测序获取表达谱,使用CIBERSORT、xCell及 ingenuity pathway分析软件计算免疫细胞。
- 统计采用t检验、卡方检验、ANOVA及Spearman秩相关,使用SPSS v21。
主要发现
- xCell和ingenuity pathway分析验证显示巨噬细胞高度参与。
- PD-L1表达可变,在肿瘤分期、水平或免疫细胞检测方面无差异。
临床怎么用
- 瘤栓中M1巨噬细胞高表达提示其可能作为未来治疗靶点。
- 临床决策时需注意原发灶活检PD-L1结果可能不代表瘤栓PD-L1状态。
- 平均血小板体积作为PD-L1表达血液标志物的潜力尚待验证,暂不宜用于临床决策。
局限性
- 样本量仅6例,结论需更大样本验证。
- 平均血小板体积与PD-L1表达的相关性需未来研究确认。
- PD-L1表达在肿瘤分期、水平或免疫细胞检测方面无差异,可能受样本量限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To perform immune-cell enumeration and programmed death-ligand 1 (PD-L1) expression in clear cell renal cell carcinoma (cc-RCC) with tumor thrombus (TT) to guide therapeutic decisions. METHODS: After obtaining IRB approval and surgical consent, 6 patients underwent radical nephrectomy with venous tumor thrombectomy. We utilized RNA Sequencing to obtain RNAseq expression profiles. Computational calculation and enumeration of immune cells were performed using CIBERSORT, xCell, and ingenuity pathway analysis software. Statistical assessment was conducted using a t test, chi-square, ANOVA and Spearman rank correlations using SPSS v21. RESULTS: We observed a higher proportion of M1 macrophages in the primary tumor and tumor thrombus, while we noted no difference in M2 macrophages despite M2 representing a high number in thrombus samples. (ANOVA, P = .032, and P = .89, respectively). Validation with xCell and ingenuity pathway analysis analysis showed a high involvement of macrophages. We observed a higher number of M1 macrophages (CIBERSORT mean 0.11 vs 0.03, P < 0.01) and (nonactivated) resting Natural Killer (NK) cells (0.077 vs 0.017, P = .02) associated PD-L1 high expression of the primary tumor. PDL1 expression was variable without differences in tumor stage, level, or immune cell detection. We observed an inverse correlation of mean platelet volume with PD-L1 expression within the primary tumor (Spearman, -0.89, P = 02) and the TT (Spearman, -0.77, P = 0.07). CONCLUSION: Renal tumor thrombus has higher levels of M1 macrophages that could be utilized as additional targets for future drug development. The PD-L1 expression on clear cell RCC biopsy may not represent its corresponding TT. Future studies are needed to confirm mean platelet volume as a potential blood-based biomarker for PD-L1 expression in RCC.
引用
- Liss MA, Chen Y, Rodriguez R, et al. Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology. 2018. PMID: 30385260. doi:10.1016/j.urology.2018.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。